Produktbild
Rongshi Li

Kinase Inhibitor Drugs

Ebook (PDF Format)

A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development. In one compreh… Mehr

CHF 113.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen
Versandkostenfrei

Produktdetails


Weitere Autoren: Stafford, Jeffrey A.
  • ISBN: 978-0-470-52495-4
  • EAN: 9780470524954
  • Produktnummer: 13957093
  • Verlag: Wiley
  • Sprache: Englisch
  • Erscheinungsjahr: 2009
  • Seitenangabe: 528 S.
  • Plattform: PDF
  • Masse: 12'563 KB

Über den Autor


Rongshi Li, PhD, is an Associate Professor in the Drug Discovery Department at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Jeffrey A. Stafford, PhD, has led drug discovery research at GlaxoSmithKline, Syrrx, and Takeda. He is a co-inventor of the tyrosine kinase inhibitor, pazopanib (Armala).

2 weitere Werke von Rongshi Li:


Bewertungen


0 von 0 Bewertungen

Geben Sie eine Bewertung ab!

Teilen Sie Ihre Erfahrungen mit dem Produkt mit anderen Kunden.